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ype 5 Phosphodiesterase
nhibition in Heart Failure
he Next Step*
teven R. Goldsmith, MD, FACC
inneapolis, Minnesota
Those who cannot remember the past are condemned to repeat it.
—George Santayana (1)
he possibility that selective inhibition of type 5 phospho-
iesterase (PDE5) might be helpful in heart failure (HF) is
urrently receiving attention. This approach consistently and
ignificantly reduces pulmonary vascular resistance (PVR) by
nhibiting the hydrolysis of cyclic guanosine monophosphate in
he pulmonary vasculature (2). As a result, right ventricular
RV) function and exercise capacity improve in patients with
ulmonary hypertension (3,4). Based on the efficacy and
afety of these compounds in that setting, several investiga-
ors have begun to study this class of therapy in patients
ith HF caused by left ventricular (LV) systolic heart failure
SHF). The creative and well-conducted study by Guazzi et
l. (5) in this issue of the Journal represents the latest of
hese investigations. The purpose of this Editorial Com-
ent is to review this study, place it in the context of current
nowledge, and suggest a possible next step in the investi-
ation of the therapeutic potential of these interesting
ompounds for SHF.
See page 2136
Guazzi et al. (5) studied the effects of sildenafil in patients
ith chronic stable SHF on contemporary neurohormonal
nhibitory therapy and diuretics. They set out 3 goals for
heir study: 1) to show that acute effects of sildenafil on a
umber of physiological parameters could be safely main-
ained with up to 6 months of treatment; 2) to investigate
he possibility that a novel mechanism, namely improving
he sensitivity of the ergo-ventilatory reflex, might contrib-
te to any benefits seen; and 3) to establish a rational basis
or further study of this compound in heart failure. How
ell did they succeed?
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.w
From the Cardiology Division, Hennepin County Medical Center, and the
niversity of Minnesota, Minneapolis, Minnesota.In my opinion, the first goal was clearly met. Compared
ith placebo, 6 months of administration of sildenafil (50
g twice daily) reduced pulmonary artery pressure (esti-
ated from echocardiographic Doppler study), improved
entilatory efficiency and peak oxygen consumption, im-
roved flow-mediated vasodilation in the brachial artery,
nd improved the sensitivity of the ergo-ventilatory reflex (a
eflex that couples mechanoreceptors and/or chemorecep-
ors in exercising skeletal muscle to the control of ventila-
ion) (6,7). Findings present in acute experiments were
eproduced at 3 and 6 months in the active treatment group.
n addition, one component of an unspecified quality-of-life
uestionnaire, breathlessness, was improved with active
reatment. There were no untoward effects of therapy.
These findings are impressive. The acute experiments
onfirm results from other acute studies in SHF (8,9). An
mportant feature of the current study design was the
ssessment of the response of all variables (other than those
ssessed on the heart failure questionnaire) to active therapy
n all subjects before randomization to minimize the chance
hat differences in response between groups could have been
aused by intrinsic differences in responsiveness. In fact,
oth groups responded identically to acute therapy, whereas
nly the sildenafil-treated group showed similar responses at
and 6 months. Interestingly, there was little difference in
he magnitude of the response of any variable between acute
dministration and 3 months of therapy with sildenafil, and
nly trends toward any additional improvement at 6 months.
he implication of the time course of these responses is clearly
hat whatever the mechanism responsible for the improve-
ents, the effect is likely to be pharmacological rather than
iological because the results of major changes in gene
xpression or structure would presumably take longer to
ecome evident.
Sildenafil therefore may be an effective agent in patients
ith chronic SHF by reducing pulmonary artery pressure
nd by improving ventilatory efficiency and exercise capacity
nd the associated symptom of breathlessness. The next
ssue is the nature of the mechanism producing these effects
nd the implications of this mechanism or mechanisms for
urther investigation. This leads to the examination of how
ell the investigators succeeded in meeting their second
oal, namely investigating the possibility that improvements
n ergo-ventilatory reflex function contribute significantly to
he hemodynamic and ventilatory effects seen. In my opin-
on, although the study shows a clear effect of sildenafil on
his reflex, any speculation about cause and effect is prema-
ure. This is an interesting reflex that has been shown to be
bnormal in patients with HF (6,7), but little is known
bout factors influencing its function. It is tempting to
ssume that improved nitric oxide donation (presumptively
he mechanism of the improved flow-mediated vasodilation
hown in the forearm circulation) also improved the func-
ion of this reflex. Proof would require future experiments
ith an inhibitor of nitric oxide generation or effect. But
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Editorial Comment November 27, 2007:2145–7hatever the mechanism by which the reflex function
mproved, it is entirely plausible that the improvement
ccurred in parallel with the other responses shown. Noth-
ng in the data allows any conclusion about causality in
ither direction (i.e., from the reflex to the ventilatory and
emodynamic responses, or vice versa). Therefore, although
hese data are novel and intriguing, the most that can really
e said is that improvements in this reflex represent another
ossible mechanism by which this class of agents might
mprove exercise capacity and ventilatory function in pa-
ients with SHF. Simply improving pulmonary perfusion as
result of lowered pulmonary vascular resistance could have
ad a major effect on physiological dead space and possibly
n other receptors and reflexes originating within the
ulmonary circulation. These effects could also have led to
mprovements in ventilatory efficiency, exercise capacity,
nd the sensation of breathlessness.
What then should we do in view of this study, which
icely extends acute experiments by their own group and
hose of others working in this field (8,9)? This question
elates to their third goal, that of providing a rational basis
or further study. Here, in my opinion, although providing
mportant data that may be useful in future studies, they
ave not made a compelling case showing that such study is
et warranted. My concern follows from important mecha-
istic questions that are not yet resolved, and that I think
eed to be resolved if we are not to find ourselves ruefully
ondering Santayana several years hence. Should we pro-
eed without more and crucial information about how these
rugs work in SHF?
The most consistent effect of these drugs is to lower PVR.
ittle if any effect is seen on systemic vascular tone (al-
hough the observation on improved flow-mediated vasodi-
ation certainly suggests activity in the peripheral circula-
ion). Cardiac output, however, frequently increases, both in
atients with primary pulmonary hypertension and in those
ith SHF (4,8–10). Furthermore, in patients with predom-
nantly RV dysfunction, cardiac output increases with sil-
enafil but not the inhalation of nitric oxide at comparable
eductions in the pulmonary vascular resistance (10). These
bservations, of course, strongly suggest an inotropic effect
f inhibiting PDE5. Yet it has been difficult to demonstrate
DE5 in human myocardium (11), and cardiac output does
ot increase when PDE5 is inhibited in normal humans or
hose with coronary disease (12,13). Other experiments in
ormal myocardium have shown that PDE5 inhibition
ctually blunts the inotropic response to adrenergic agonists
14). At a minimum, one would have to conclude that the
ctions of PDE5 and its inhibition in normal myocardium
re unclear, and may depend on whether effects are assessed
nder basal conditions or with adrenergic stimulation.
A recent and important investigation by Nagendran et al.
15), however, extends our knowledge of this physiology by
tudying PDE5 effects in abnormal human myocardium.
hese investigators confirmed that although PDE5 was notound in normal human RV myocardium, it was found in
Miseased, hypertrophied RV myocardium, and it was possi-
le to show an inotropic effect of PDE5 inhibition in this
issue. The proposed mechanism is indirect inhibition of
DE3 as a result of increased guanosine monophosphate
ignaling, with subsequent cyclic adenosine monophosphate-
ediated effects as would be expected. In the accompanying
ditorial, Kass (16) notes that although these findings
onflict to some extent with other reported data and will
equire confirmation, the data are intriguing and may help
o reconcile the apparent paradox of an inotropic effect of
DE5 inhibition in patients with RV dysfunction, but not
n normal subjects. Nagendran et al. (15) laud this finding as
et another reason that this type of therapy might be
ffective in primary pulmonary hypertension with abnormal
V function. However, if the same type of response were to
e demonstrable in diseased, hypertrophied left ventricular
issue (and as Kass [16] notes, this seems more likely than
ot), there would be significant cause for concern about the
afety of long-term administration of these agents in pa-
ients with SHF. We have learned, painfully and repeatedly,
hat inotropic intervention in HF, including that based on
DE3 inhibition, is dangerous (17).
In view of these considerations, I believe the next step in
he development of PDE5 inhibitory therapy for SHF
hould be to repeat the experiments of Nagendran et al. (15)
n human LV myocardial tissue. If the results are negative,
n view of the promising signals from the small clinical series
eported to date, a larger outcomes trial would be reason-
ble. However, if PDE5 is found in LV tissue, and if an
notropic effect is shown as a result of its inhibition, then a
ery hard look would have to be taken at the possible clinical
elevance of such findings. A possible increase in mortality
aused by chronic inotropic stimulation would have to be set
gainst the likelihood of symptomatic improvement from
he effects of PDE5 inhibition in the lung. It is true, of
ourse, that the use of angiotensin-converting enzyme
nhibitors, angiotensin receptor blockers, aldosterone antag-
nists, adrenergic antagonists, and defibrillators might di-
inish the risks of chronic low-dose PDE3 inhibition in
HF. But we do not know that, whereas we do have the
ools and techniques at our disposal to learn whether such
oncerns should enter into consideration of future develop-
ent of these compounds. In other words, we have the
bility not only to remember our past history with other
gents that inhibit phosphodiesterase in chronic SHF, but
lso to avoid repeating previous mistakes. I believe we
hould make every attempt to do so before embarking on
arger trials in SHF with these interesting and potentially
seful compounds.
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